PT3817813T - Sais cristalinos de ácido 5metil-(6s)-tetra.hidrofólico e de éster etílico de l-leucina - Google Patents
Sais cristalinos de ácido 5metil-(6s)-tetra.hidrofólico e de éster etílico de l-leucinaInfo
- Publication number
- PT3817813T PT3817813T PT197374960T PT19737496T PT3817813T PT 3817813 T PT3817813 T PT 3817813T PT 197374960 T PT197374960 T PT 197374960T PT 19737496 T PT19737496 T PT 19737496T PT 3817813 T PT3817813 T PT 3817813T
- Authority
- PT
- Portugal
- Prior art keywords
- methyl
- ethyl ester
- tetrahydrofolic acid
- crystalline salts
- leucine ethyl
- Prior art date
Links
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical class C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 title 1
- QIGLJVBIRIXQRN-ZETCQYMHSA-N ethyl (2s)-2-amino-4-methylpentanoate Chemical class CCOC(=O)[C@@H](N)CC(C)C QIGLJVBIRIXQRN-ZETCQYMHSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18182279 | 2018-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3817813T true PT3817813T (pt) | 2023-12-22 |
Family
ID=62874793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT197374960T PT3817813T (pt) | 2018-07-06 | 2019-07-02 | Sais cristalinos de ácido 5metil-(6s)-tetra.hidrofólico e de éster etílico de l-leucina |
Country Status (12)
Country | Link |
---|---|
US (1) | US11925644B2 (pt) |
EP (1) | EP3817813B1 (pt) |
JP (1) | JP7473526B2 (pt) |
CN (1) | CN112312968A (pt) |
AU (1) | AU2019297312A1 (pt) |
CA (1) | CA3105545A1 (pt) |
DK (1) | DK3817813T3 (pt) |
ES (1) | ES2966940T3 (pt) |
FI (1) | FI3817813T3 (pt) |
HU (1) | HUE064731T2 (pt) |
PT (1) | PT3817813T (pt) |
WO (1) | WO2020007839A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112125906A (zh) * | 2020-10-27 | 2020-12-25 | 哈尔滨理工大学 | S-5-甲基四氢叶酸氨基酸酯盐及其合成方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
CN103664945B (zh) * | 2012-09-07 | 2016-01-20 | 南京莱因医药科技有限公司 | L-5-甲基四氢叶酸氨基酸盐的制备方法 |
US20160207925A1 (en) | 2013-12-31 | 2016-07-21 | Gianni Fracchia | L-methylfolate salt preparations, medicaments, and nutritional supplements comprising such salts thereof |
CN107304212A (zh) * | 2016-04-21 | 2017-10-31 | 常州爱诺新睿医药技术有限公司 | 一种无定型l-5-甲基四氢叶酸氨基酸盐及其制备方法 |
-
2019
- 2019-07-02 FI FIEP19737496.0T patent/FI3817813T3/fi active
- 2019-07-02 US US17/258,086 patent/US11925644B2/en active Active
- 2019-07-02 DK DK19737496.0T patent/DK3817813T3/da active
- 2019-07-02 CA CA3105545A patent/CA3105545A1/en active Pending
- 2019-07-02 WO PCT/EP2019/067698 patent/WO2020007839A1/en unknown
- 2019-07-02 JP JP2021500074A patent/JP7473526B2/ja active Active
- 2019-07-02 PT PT197374960T patent/PT3817813T/pt unknown
- 2019-07-02 HU HUE19737496A patent/HUE064731T2/hu unknown
- 2019-07-02 ES ES19737496T patent/ES2966940T3/es active Active
- 2019-07-02 AU AU2019297312A patent/AU2019297312A1/en active Pending
- 2019-07-02 CN CN201980043620.4A patent/CN112312968A/zh active Pending
- 2019-07-02 EP EP19737496.0A patent/EP3817813B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2966940T3 (es) | 2024-04-25 |
WO2020007839A1 (en) | 2020-01-09 |
US11925644B2 (en) | 2024-03-12 |
EP3817813A1 (en) | 2021-05-12 |
US20210283136A1 (en) | 2021-09-16 |
AU2019297312A1 (en) | 2021-03-04 |
EP3817813B1 (en) | 2023-09-20 |
JP2021529802A (ja) | 2021-11-04 |
CN112312968A (zh) | 2021-02-02 |
JP7473526B2 (ja) | 2024-04-23 |
HUE064731T2 (hu) | 2024-04-28 |
CA3105545A1 (en) | 2020-01-09 |
DK3817813T3 (da) | 2023-12-11 |
FI3817813T3 (fi) | 2023-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201804870B (en) | Acid addition salts of piperazine derivatives | |
IL279101A (en) | Salts of spiafatrin are accepted in pharmacies | |
MX2018003649A (es) | Metodos e intermedios para la preparacion de derivados de acido biliar. | |
IL273579A (en) | Salts of pyrrolothrizine compounds used as tem inhibitors. | |
IL280841A (en) | Succinate and fumarate acid addition salts of piperazine derivatives used as glycosidase inhibitors | |
EP3853852A4 (en) | DYNAMIC CONFIGURATION OF MEMORY SYNCHRONIZATION PARAMETERS | |
EP3408254A4 (en) | SALTS OF 5-AMINOLÄVULINIC ACID AND DERIVATIVES | |
EP3790881A4 (en) | LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES | |
PT3817813T (pt) | Sais cristalinos de ácido 5metil-(6s)-tetra.hidrofólico e de éster etílico de l-leucina | |
MX2019003684A (es) | Formas cristalinas de un derivado de acido biliar. | |
HUE064746T2 (hu) | 5-Metil-(6S)-tetrahidrofolsav és l-valin-etilészter kristályos sói | |
PT3817812T (pt) | Sal cristalino de acido 5-metil-(68)-tetra-hidrofólico e éster etílico de l-isoleucina | |
IL269073A (en) | Crystalline forms of obeticholic acid | |
EP3445751A4 (en) | NEW POLYMORPHE FORM OF CRYSTALLINE ROSUVASTATIN CALCIUM AND NEW PROCESSES FOR CRYSTALLINE AND AMORPHIC ROSUVASTATIN CALCIUM | |
HUE064729T2 (hu) | 5-Metil-(6S)-tetrahidrofolsavat és 4-(2-hidroxietil)-morfolint tartalmazó kristályos só | |
IL274758A (en) | Crystalline forms of praquinostat | |
SG11202108905UA (en) | Crystalline form of an avibactam derivative | |
EP3896063A4 (en) | SYK INHIBITOR SALT AND CORRESPONDING CRYSTALLINE FORM | |
GB201912411D0 (en) | Crystalline forms of ivosidenib | |
ZA202008062B (en) | Pharmaceutically acceptable salts of sepiapterin | |
EP3887367A4 (en) | CRYSTALLINE SALTS OF CORYDALMINE | |
EP4069674A4 (en) | CRYSTALLINE FORM I OF BUCILLAMIN | |
EP3781155A4 (en) | MEGLUMINAL SALT OF THIENOPYRIMIDINES | |
EP3837356A4 (en) | AMORPHIC AND CRYSTALLINE FORMS OF VALBENAZINE SALT | |
GB202009218D0 (en) | Crystalline forms of entrectinib |